HC Wainwright & Co. Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $90
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $90.
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $90.